Meeting of the Internal Medicine Sciences’ Council of the Department of Medical Sciences of the Russian Academy of Sciences on April 29, 2025, "Marathon of Research Projects from Russian Internal Medicine Departments: 'From Innovative Technologies and Education to Healthcare Practice'. Application of Personalized Medicine Approaches in Internal Medicine Practice"

internal medicine, Internal Medicine Sciences’ Council of the Russian Academy of Sciences, personalized medicine, pharmacogenomics, artificial intelligence, machine learning, autoimmune gastritis, frailty syndrome, heart failure, irritable bowel syndrome

1. Kontsevaya AV, Romanenko TS, Vygodin VA, et al. Phar­ma­co­epidemiology and the Efficacy of Antihypertensive Treatment in Real-­Life Practice of the Cardiology Referral Clinic. Rational Phar­macotherapy in Cardiology. 2015;11(1):8-17. (In Russ.) doi:10.20996/1819-6446-2015-11-1-8-17.

2. De Backer G, Jankowski P, Kotseva K, et al. Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries. Atherosclerosis. 2019;285:135-46. doi:10.1016/j.atherosclerosis.2019.03.014.

3. Misnikova IV, Dreval' AV, Kovaleva YuA. Glycated Hemoglobin as a Key Parameter in Diabetes Control. Diabetes mellitus. 2008; (4):38-40. (In Russ.) doi:10.14341/2072-0351-5588.

4. Mesitskaia DF, Nikitina YuM, Kopylov FIu, et al. Resistance to clopidogrel: do we know everything? Russian Journal of Car­dio­logy and Cardiovascular Surgery. 2013;6(1):27-32. (In Russ.)

5. Vavilova TV. Anticoagulants in clinical practice. The place of vi­tamin K antagonists in combination with new oral anti­co­agulants. Meditsinskiy sovet = Medical Council. 2015;(12): 44-7. (In Russ.) doi:10.21518/2079-701X-2015-12-44-47.

6. Nazarenko GI, Kleymenova EB, Otdelenov VA, et al. The use of adverse event triggers to identify adverse drug reactions in a multidisciplinary hospital. Clinical Pharmacology and Therapy. 2015;24(4):55-62. (In Russ.)

7. Rytkin E, Kriukova K, Denisenko N, et al. Editorial: The utilization of bench-to-bedside approaches in pharmacogenomics. Front Pharmacol. 2023;14:1234219. doi:10.3389/fphar.2023.1234219.

8. Sychev D, Fedina L, Poptsova M, et al. A survey of physician opi­nions in Russia in the field of pharmacogenetics of cardiovascular disease. Pharmacogenomics. 2022;23(15):847-56. doi:10.2217/pgs-2022-0048.

9. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modi­fiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937-52. doi:10.1016/S0140-6736(04)17018-9.

10. O'Donnell MJ, Chin SL, Rangarajan S, et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet. 2016;388(10046):761-75. doi:10.1016/S0140-6736(16)30506-2.

11. Ershova AI, Balakhonova TV, Meshkov AN, et al. Prevalence of ca­rotid and femoral artery atherosclerosis among the Ivanovo Oblast population: data from the ATEROGEN-Ivanovo study. Car­diovascular Therapy and Prevention. 2021;20(5):2994. (In Russ.) doi:10.15829/1728-8800-2021-2994.

12. Erina AM, Usoltsev DA, Boyarinova MA, et al. Appointment of li­pid-lowering therapy in the Russian population: comparison of SCORE and SCORE2 (according to the ESSE-RF study). Russian Journal of Cardiology. 2022;27(5):5006. (In Russ.) doi:10.15829/1560-4071-2022-5006.

13. Jamthikar A, Gupta D, Saba L, et al. Cardiovascular/stroke risk predictive calculators: a comparison between statistical and ma­chine learning models. Cardiovasc Diagn Ther. 2020;10(4):919-38. doi:10.21037/cdt.2020.01.07.

14. Ambale-­Venkatesh B, Yang X, Wu CO, et al. Cardiovascular Event Prediction by Machine Learning: The Multi-­Ethnic Study of Athe­ro­sclerosis. Circ Res. 2017:121(9):1092-101. doi:10.1161/CIRCRESAHA.117.311312.

15. Nevzorova VA, Plekhova NG, Priseko LG, et al. Machine learning for predicting the outcomes and risks of cardiovascular diseases in patients with hypertension: results of ESSE-RF in the Primorsky Krai. Russian Journal of Cardiology. 2020;25(3):3751. (In Russ.) doi:10.15829/1560-4071-2020-3-3751.

16. Nevzorova VA, Brodskaya TA, Shakhgeldyan KI, et al. Machine lear­ning for predicting 5-year mortality risks: data from the ESSE-RF study in Primorsky Krai. Cardiovascular Therapy and Prevention. 2022;21(1):2908. (In Russ.) doi:10.15829/1728-8800-2022-2908.

17. Bogdanov DYu, Nevzorova VA, Shahgeldyan KI, et al. Mathe­ma­tical model possibility of the risk of developing atherosclerosis among 30-49 years old of Slavic and Korean population. Systemic Hypertension. 2022;19(2):27-32. (In Russ.) doi:10.38109/2075-082X-2022-2-27-32.

18. Gusev AV, Gavrilov DV, Novitsky RE, et al. Improvement of car­diovascular risk assessment using machine learning methods. Russian Journal of Cardiology. 2021;26(12):4618. (In Russ.) doi:10.15829/1560-4071-2021-4618.

19. Castellana C, Eusebi LH, Dajti E, et al. Autoimmune Atrophic Gastritis: A Clinical Review. Cancers (Basel). 2024;16(7):1310. doi:10.3390/cancers16071310.

20. Kaibysheva V, Drapkina O, Maev I, et al. Diagnosis and treatment of autoimmune gastritis. Guidelines. М.: ROPNIZ, 2024. p. 40. (In Russ.) doi:10.15829/ROPNIZ-k8-2024.

21. Tsukanov VV, Tret'yakova OV, Amelchugova OS, et al. The pre­va­len­ce of atrophic gastritis of the body of stomach at Krasno­yarsk population over 45 years old. Russian Journal of Gas­tro­en­te­ro­logy, Hepatology, Coloproctology. 2012;22(4):27-31. (In Russ.)

22. Kulnigg-­Dabsch S. Autoimmune gastritis. Wien Med Wochenschr. 2016;166(13-14):424-30. doi:10.1007/s10354-016-0515-5.

23. Cavalcoli F, Zilli A, Conte D, et al. Micronutrient deficiencies in pa­tients with chronic atrophic autoimmune gastritis: A review. World J Gastroenterol. 2017;23(4):563-72. doi:10.3748/wjg.v23.i4.563.

24. Furuta T, Baba S, Yamade M, et al. High incidence of autoimmune gastritis in patients misdiagnosed with two or more failures of H. pylori eradication. Aliment Pharmacol Ther. 2018;48(3):370-7. doi:10.1111/apt.14849.

25. Ivashkin VT, Maev IV, Lapina TL, et al. Clinical Recommendations of Russian Gastroenterological Association and RENDO Endo­sco­pic Society on Diagnosis and Treatment of Gastritis and Duodenitis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(4):70-99. (In Russ.) doi:10.22416/1382-4376-2021-31-4-70-99.

26. Shah SC, Piazuelo MB, Kuipers EJ, et al. AGA Clinical Practice Update on the Diagnosis and Management of Atrophic Gastritis: Expert Review. Gastroenterology. 2021;161(4):1325-32. doi:10.1053/j.gastro.2021.06.078.

27. Rugge M, Genta RM, Malfertheiner P, et al. RE.GA.IN.: the Real-world Gastritis Initiative-­updating the updates. Gut. 2024;73(3): 407-41. doi:10.1136/gutjnl-2023-331164.

28. Lenti MV, Rugge M, Lahner E, et al. Autoimmune gastritis. Nat Rev Dis Primers. 2020;6(1):56. doi:10.1038/s41572-020-0187-8.

29. Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence con­sen­sus report. Gut. 2022. doi:10.1136/gutjnl-2022-327745.

30. Ivashkin VT, Maev IV, Lapina TL, et al. H. pylori-­Associated Gas­tritis, Gastritis after H. pylori Eradication and H. pylori-­Ne­ga­tive Gastritis: Algorithm of Diagnosis and Treatment (Literature Review and Resolution of the Expert Panel of the Russian Gastroenterological Association). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2024;34(3):7-23. (In Russ.) doi:10.22416/1382-4376-2024-34-3-7-23.

31. Bakulin IG, Sushilova AG, Zharkov AV, et al. Effectiveness of 6-Month Rebamipide Therapy in Chronic Atrophic Gastritis: Results of the OPLOT Study. Effective Pharmacotherapy. 2024;20(46):28-34. (In Russ.) doi:10.33978/2307-3586-2024-20-46-28-34.

32. Fomin IV. Chronic Heart Failure in Russian Federation: What Do We Know and What to Do. Russian Journal of Cardiology. 2016;(8):7-13. (In Russ.) doi:10.15829/1560-4071-2016-8-7-13.

33. Larina VN. Modern vision on the problem of chronic heart failure in the older persons. Russian Journal of Geriatric Medicine. 2021;(1):65-75. (In Russ.) doi:10.37586/2686-8636-1-2021-65-75.

34. Denfeld QE, Winters-­Stone K, Mudd JO, et al. The prevalence of frailty in heart failure: A systematic review and meta-analysis. Int J Cardiol. 2017;236:283-9. doi:10.1016/j.ijcard.2017.01.153.

35. Safronenko VA, Chesnikova AI, Safronenko AV. The parameters of the daily blood pressure profile in hypertensive patients de­pen­ding on the presence of chronic heart failure and senile asthenia syndrome. Arterial’naya Gipertenziya = Arterial Hyper­tension. 2025;31(2):136-47. (In Russ) doi:10.18705/1607-419X-2025-2486.

36. Safronenko VA, Chesnikova AI, Korobka VL. Diagnostic value of cardiac marker concentrations in patients with heart failure depending on frailty syndrome. Russian Journal of Cardiology. 2024;29(9):5830. (In Russ.) doi:10.15829/1560-4071-2024-5830.

37. Sperber AD, Bangdiwala SI, Drossman DA, et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology. 2021;160(1):99-114. doi:10.1053/j.gastro.2020.04.014.

38. Ghaffari P, Shoaie S, Nielsen LK. Irritable bowel syndrome and microbiome; Switching from conventional diagnosis and the­rapies to personalized interventions. J Transl Med. 2022;20(1): 173. doi:10.1186/s12967-022-03365-z.

39. Longstreth GF, Yao JF. Irritable bowel syndrome and surgery: a multivariable analysis. Gastroenterology. 2004;126(7):1665-73. doi:10.1053/j.gastro.2004.02.020.

40. Drossman DA, Hasler WL. Rome IV-Functional GI Disorders: Dis­orders of Gut-­Brain Interaction. Gastroenterology. 2016;150(6): 1257-61. doi:10.1053/j.gastro.2016.03.035.

41. Sperber AD, Freud T, Aziz I, et al. Greater Overlap of Rome IV Dis­orders of Gut-­Brain Interactions Leads to Increased Disease Severity and Poorer Quality of Life. Clin Gastroenterol Hepatol. 2022;20(5):e945-e956. doi:10.1016/j.cgh.2021.05.042.

42. Van Oudenhove L, Crowell MD, Drossman DA, et al. Biopsy­cho­social Aspects of Functional Gastrointestinal Disorders. Gastroenterology. 2016. doi:10.1053/j.gastro.2016.02.027.

43. Malan-­Müller S, Martín-­Hernández D, Caso JR, et al. Meta­ge­no­mic symphony of the intestinal ecosystem: How the composition affects the mind. Brain Behav Immun. 2025;123:510-23. doi:10.1016/j.bbi.2024.09.033.

44. Huang KY, Wang FY, Lv M, et al. Irritable bowel syndrome: Epidemiology, overlap disorders, pathophysiology and treatment. World J Gastroenterol. 2023;29(26):4120-35. doi:10.3748/wjg.v29.i26.4120.

45. Gaus OV, Livzan MA. Irritable bowel syndrome phenotypes: leading factors of genetics and epigenetics, mechanisms of formation. Terapevticheskii Arkhiv. 2023;95(2):164-72. (In Russ.) doi:10.26442/00403660.2023.02.202111.

46. Gaus OV, Livzan MA. "Gastrointestinal" comorbidity in irritable bowel syndrome. Experimental and Clinical Gastroenterology. 2021;1(6):104-11. (In Russ.) doi:10.31146/1682-8658-ecg-190-6-104-111.

47. Gaus OV, Livzan MA, Gavrilenko DA. Post-infectious irritable bowel syndrome: renaissance time? Medical alphabet. 2021; (35):23-8. (In Russ.) doi:10.33667/2078-5631-2021-35-23-28.

48. Fedorin MM, Livzan MA, Gaus OV. IBS in overweight and obese individuals: a new disease phenotype? Russian Journal of Evi­dence-­Based Gastroenterology. 2021;10(2):52-60. (In Russ.) doi:10.17116/dokgastro20211002152.